CQN-ALTER-DOMUS
Third bullet in the body of the release should read: "Tailored benchmarking against peers and operational support" (instead of "Tailored benchmarking against peers and operational advisory")
The updated release reads:
ALTER DOMUS LAUNCHES INDUSTRY-LEADING ESG REPORTING SOLUTION FOR ALTERNATIVE INVESTMENT MANAGERS
Fund administrator unveils comprehensive and innovative ESG solution that provides regulatory and signatory support for clients
Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has launched an industry-leading Environmental, Social & Governance (ESG) reporting solution.
Despite a lack of standardized ESG models available, demand for ESG data is booming.1 This trend has placed additional strain on alternatives managers who are increasingly fielding ESG data requests from investors, regulators, and non-governmental organizations without a clear directive on how to report or share this data.
Designed specifically for alternative assets, Alter Domus’ ESG Reporting Solution is a cloud-based digital platform that provides comprehensive, tailored reports for clients that collect, store, and disseminate corporate ESG data. Alter Domus’ ESG Reporting Solution will be accessible through an online, user-friendly portal that ensures secure access and management of client data.
Other features of Alter Domus’ ESG Reporting Solution include:
- Scoring and ratings for a fund or portfolio based on internationally recognized standards
- Data analysis that can be shared with stakeholders, including regulators for disclosure, compliance, and other reporting purposes
- Tailored benchmarking against peers and operational support
“Today’s announcement underscores Alter Domus’ commitment to developing and offering the most innovative products that our clients need at a global scale,” said Alex Traub, Chief Commercial Officer. “ESG has become an important part of investment philosophies for investors at every level, and we expect this trend to continue even further as ESG becomes more standardized and mainstream with alternative managers.”
“We have heard from our clients globally about the need for a standardized ESG reporting framework and solution that can be integrated across all of their operations seamlessly,” said Antonis Anastasiou, Managing Director of the Alter Domus Management Company S.A. “We worked to develop this solution that helps our clients not only navigate the complexities of ESG regulation, but to also provide their own investors with the types of reporting they need.”
For its part, and as a growing organization with an increasingly global footprint, Alter Domus ensures that ESG factors are considered as standard practice in all strategic business planning and decision making. Further, Alter Domus is a signatory of the United Nations-supported Principles for Responsible Investment, and aligned with The World Economic Forum (WEF) Measuring Stakeholder Capitalism; Towards Common Metrics and Consistent Reporting of Sustainable Value Creation framework.
Over the last 12 months, Alter Domus has seen increasing demand for alternative investments, particularly in Europe and the United States. Having doubled their assets under administration in that time, Alter Domus is at the forefront of delivering timely, technology-driven solutions to alternative asset managers, lenders, and asset owners globally.
About Alter Domus
Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .
____________________
1
Opimas Research: http://www.opimas.com/research/547/detail/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom